在2025年美国临床肿瘤学会(ASCO)年度会议上,辉瑞公司公布了其激酶抑制剂Braftovi(Encorafenib)在治疗BRAF V600E突变型转移性结直肠癌(mCRC)方面取得了具有重大意义的成果,有望使其加速获批的Braftovi转化为全面批准。此次突破得益于III期BREAKWATER研究针对BRAF V600E突变型转移性结直肠癌(mCRC)患者的最新生存数据,辉瑞或许能够迅速将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.